BioMarin and Serono Announce Data on Phenoptin in PKU to be Presented at the 56th Annual Meeting of the American Society of Huma
September 12 2006 - 8:00AM
PR Newswire (US)
NOVATO, Calif. and GENEVA, Sept. 12 /PRNewswire-FirstCall/ --
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) and Serono
(virt-x: SEO and NYSE: SRA) today announced data from clinical
studies of Phenoptin(TM) (sapropterin dihydrochloride), an
investigational oral small-molecule therapeutic for the treatment
of phenylketonuria (PKU), that will presented at the 56th Annual
Meeting of the American Society of Human Genetics (ASHG) being held
in New Orleans, Louisiana, October 9 to 13, 2006. Data to be
presented is summarized below. ASHG Program # 57: Phase 3 Clinical
Study of Phenoptin for PKU Results from the Phase 3, double-blind,
placebo-controlled clinical study of Phenoptin (commonly referred
to as 6R-BH4, or BH4) in patients with elevated blood phenylalanine
(Phe) levels demonstrated a statistically significant reduction at
six weeks in blood Phe levels (p